Champions Oncology Inc (NASDAQ:CSBR) Director Daniel Newman Mendelson sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $13.75, for a total value of $68,750.00. Following the transaction, the director now owns 57,500 shares in the company, valued at approximately $790,625. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Daniel Newman Mendelson also recently made the following trade(s):
- On Thursday, September 20th, Daniel Newman Mendelson sold 8,333 shares of Champions Oncology stock. The stock was sold at an average price of $13.02, for a total value of $108,495.66.
Shares of CSBR stock opened at $13.80 on Friday. Champions Oncology Inc has a twelve month low of $3.05 and a twelve month high of $17.90. The company has a market capitalization of $168.70 million, a price-to-earnings ratio of -98.57 and a beta of 0.57. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23.
Champions Oncology (NASDAQ:CSBR) last announced its earnings results on Thursday, September 13th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.03. Champions Oncology had a negative return on equity of 97.02% and a negative net margin of 1.63%. The company had revenue of $6.23 million for the quarter, compared to the consensus estimate of $5.85 million. On average, equities analysts expect that Champions Oncology Inc will post 0.17 EPS for the current year.
Several hedge funds have recently made changes to their positions in CSBR. BlackRock Inc. purchased a new position in shares of Champions Oncology in the 2nd quarter valued at approximately $104,000. Bank of Montreal Can purchased a new position in shares of Champions Oncology in the 3rd quarter valued at approximately $250,000. Oppenheimer & Co. Inc. purchased a new position in shares of Champions Oncology in the 3rd quarter valued at approximately $344,000. ClariVest Asset Management LLC purchased a new position in shares of Champions Oncology in the 3rd quarter valued at approximately $536,000. Finally, Renaissance Technologies LLC grew its stake in shares of Champions Oncology by 63.3% in the 2nd quarter. Renaissance Technologies LLC now owns 100,600 shares of the biotechnology company’s stock valued at $638,000 after purchasing an additional 39,000 shares during the last quarter. Institutional investors own 40.68% of the company’s stock.
A number of research firms recently issued reports on CSBR. Zacks Investment Research upgraded Champions Oncology from a “hold” rating to a “strong-buy” rating and set a $12.00 price target on the stock in a research note on Monday, September 17th. Craig Hallum initiated coverage on Champions Oncology in a research note on Tuesday, July 17th. They issued a “buy” rating and a $12.00 target price on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $11.33.
TRADEMARK VIOLATION NOTICE: “Champions Oncology Inc (CSBR) Director Sells $68,750.00 in Stock” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/10/champions-oncology-inc-csbr-director-sells-68750-00-in-stock.html.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.